Tumor suppressor genes, treatments, and survival in US Veterans with prostate cancer

Abstract: BACKGROUND: Tumor suppressor gene (TSG) alterations prognosticate inferior survival in metastatic hormone-sensitive prostate cancer (mHSPC) and may affect response to …

Genomic risk model to implement precision prostate cancer screening in clinical care: The ProGRESS study

Abstract: Precision healthcare aims to tailor disease prevention and early detection to individual risk. Prostate cancer screening may benefit from genomics-informed approaches. We …

Does the VA risk analysis index overestimate frailty in patients with localized prostate cancer?

Abstract: INTRODUCTION AND OBJECTIVES: The Veterans Affairs (VA) Health System recently implemented the Risk Analysis Index (RAI) to assess frailty prior to surgery. Elevated RAI …

Validation of the Prostatype® P-score for predicting prostate cancer specific mortality in a multiethnic U.S. Veterans cohort

Abstract: BACKGROUND: The Prostatype® Test evaluates expression levels of three stem cell genes (IGFBP3, F3, and VGLL3), which are combined with PSA, stage, and grade to calculate …

The impact of race on survival and treatment in Veterans treated for metastatic castration-resistant prostate cancer

Abstract: Background: Black individuals have higher incidence and mortality rates of prostate cancer than White individuals, and existing literature on treatment sequencing …

Racial differences in adverse events after androgen deprivation in Veterans with prostate cancer

Abstract: Importance: Androgen deprivation therapy (ADT) for prostate cancer (PC) has been linked to adverse events, such as cardiac events and osteoporosis. Whether these …

MRI utilization rates for Veterans at risk of prostate cancer

Abstract: This cross-sectional study evaluates trends in the utilization of and disparities in prostate magnetic resonance imaging (MRI) across the Veterans Health Administration.

Abiraterone vs enzalutamide among US Veterans with metastatic hormone-sensitive prostate cancer

Abstract: Importance: The choice of first line hormonal therapy in metastatic hormone-sensitive prostate cancer (mHSPC) is often based on comorbidities or physician preference due …

Retrospective analysis of racial differences in treatment patterns and prostate-specific antigen responses among patients with prostate cancer treated with Relugolix in the Veterans Health Administration

Abstract: Introduction: Relugolix is the only oral androgen deprivation therapy (ADT) approved for advanced prostate cancer (PC). Real-world evidence on treatment patterns and …

Prostate cancer incidence and outcomes among Vietnam Veterans receiving care in the Veterans Health Administration

Abstract: BACKGROUND: Agent Orange exposure (AOE) is considered a presumptive cause of prostate cancer (PCa) in the Veterans Affairs (VA) population; however, cohort studies …

Glycemic control and prostate cancer mortality risk in Veterans with type 2 diabetes mellitus

Abstract: This retrospective cohort study of veterans diagnosed with diabetes mellitus evaluated the association between time-varying measures of glycemic control and the time to …

Racial differences in benign prostatic hyperplasia diagnosis and management in the United States Veteran population

Abstract: INTRODUCTION: Benign prostatic hyperplasia (BPH) epidemiology has been broadly investigated. However, less is known about how race affects BPH diagnosis and management. …